Progress of mesenchymal stem cells in the treatment of bronchopulmonary dysplasia / 国际儿科学杂志

ABSTRACT

Bronchopulmonary dysplasia(BPD) is a chronic lung disease in the premature infants, which is an important cause of poor prognosis in the premature infants.The pathogenesis of BPD involves a variety of prenatal and postnatal mechanisms affecting the development of immature lungs.The combined effect of BPD alters lung morphogenesis, disrupts capillary gas exchange in the alveoli, and leads to pathological and clinical features of BPD.The current clinical methods used to treat BPD are still difficult to improve its prognosis.Mesenchymal stem/stromal cell(MSC) is a promising and innovative therapy for the treatment of a wide range of diseases due to the ease of extraction, low immunogenicity, anti-inflammatory properties and regenerative ability.In recent years, many experimental and clinical studies have found and proved that mesenchymal stem cell transplantation has a certain effect on BPD, so MSC may become the promising treatment for BPD in the future.However, the possibility that MSC may promote tumor growth, the presence of heterogeneous cell populations resulting in different efficacy, and ethical issues regarding the use of this treatment in humans make it a number of therapeutic challenges.This article reviews the mechanism of action and treatment of MSC in BPD, as well as the research progress in the treatment of BPD with MSC.